Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of QLC1401 combined with a CDK4/6 inhibitor or an mTOR inhibitor in ER-positive, HER2-negative advanced or metastatic breast cancer
CTR20253558Phase 2Active
- Sponsor
- Shenzhen Yangli Pharmaceutical Technology Co. Ltd.
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of QLC1401 in breast cancer, sponsored by Shenzhen Yangli Pharmaceutical Technology Co. Ltd.. Started Oct 2025; status: active.
02
Drugs
QLC1401
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20253558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253558.